Covance Not Cooling...
Health Care: Drugs
Aegerion Pharmaceuticals Inc. (AEGR: NASDAQ)
$61.57 -0.13 | -0.21%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -62.26M | -39.47M | -14.25M | -12.20M |
| Operating Gains/Losses | 766.00K | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 2.15M | -347.30K | 1.73M | -425.00K |
| (Decrease) Increase In Other Current Liabilities | 4.22M | 3.21M | 277.74K | -166.85K |
| (Increase) Decrease In Other Working Capital | 11.00K | -171.52K | 0.00 | 0.00 |
| Other Non-Cash Items | 11.98M | 6.28M | 4.20M | 2.15M |
| Net Cash From Continuing Operations | -42.56M | -30.51M | -8.50M | -10.53M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -42.56M | -30.51M | -8.50M | -10.53M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 2.26M | 16.91M | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -815.00K | -631.31K | -11.72K | 0.00 |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -54.42M | -62.81M | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -28.00K | -46.53M | -11.72K | 0.00 |
| Issuance of Debt | 10.61M | 10.00M | 7.50M | 5.00M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 53.72M | 49.58M | 50.80M | 0.00 |
| Repayment of Long-Term Debt | -10.88M | 0.00 | -5.48M | -2.04M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -75.00K | -243.55K | -1.64M | 0.00 |
| Net Cash From Financing Activities | 53.38M | 59.33M | 51.18M | 2.96M |
| Effect of Exchange Rate Changes | 8.00K | -24.86K | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 10.80M | -17.73M | 42.67M | -7.58M |
Portfolios with AEGR
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Rising On Unusal Vol...
- ContributorStocks With Big Insider Buy...
Latest AEGR Headlines from TheStreet
- Aegerion Pharmaceuticals To Announce First Quarter 2013 Financial Results On Tuesday, April 30 04.16.13 | 08:04 am
- Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program 04.03.13 | 04:04 pm
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- 10 Stocks Insiders And Hedge Funds Think Will Go Higher 03.11.13 | 01:03 pm
- Aegerion Pharmaceuticals Announces Fourth-Quarter And Year-End 2012 Financial Results 03.06.13 | 07:03 am
- Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program 03.05.13 | 04:03 pm
- 5 Stocks Set to Soar on Bullish Earnings 03.04.13 | 01:03 pm
- Aegerion Pharmaceuticals Observes Rare Disease Day 02.28.13 | 08:02 am
- Aegerion Pharmaceuticals Announces Presentation At The Cowen And Company 33rd Annual Health Care Conference 02.27.13 | 08:02 am
- Aegerion Pharmaceuticals To Announce Fourth Quarter 2012 Financial Results On Wednesday, March 6 02.20.13 | 08:02 am
Press Releases for AEGR
- Insmed Appoints Will Lewis As President And Chief Executive Officer - PR Newswire 09.11.12 | 08:09 am
- Aegerion Pharmaceuticals Chief Executive Officer Marc D. Beer (Video: Business Wire) - Business Wire 09.29.11 | 08:09 am
Partner Headlines for AEGR
- Insider Buying Trends: Are These Cash Rich Companies Ready To Rally? - Seeking Alpha 03.15.13 | 09:03 am
- UPDATE: Canaccord Genuity Raises PT to $44 on Aegerion Pharmaceuticals on Encouraging Sales Data - Benzinga 03.07.13 | 01:03 pm
- UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Strong Juxtapid Uptake - Benzinga 03.06.13 | 01:03 pm
- Pre-Market Earnings Report for March 6, 2013 : SPLS, BF/B, AEO, TFM, BIG, AEGR, HOV, WD, TRK, QRE, WILN, MFB - NASDAQ 03.05.13 | 09:03 pm
- Calendar Spreads On Intuitive Surgical, Riverbed Technology And Sandisk - Seeking Alpha 10.19.12 | 09:10 am
- Benzinga Mid-Day Market Update - Benzinga 10.17.12 | 12:10 pm
- 5 Pharmaceutical Companies With EMA Catalysts During The Next 3 - 12 Months - Part II - Seeking Alpha 09.02.12 | 08:09 am
- Aegerion Pharmaceuticals Announces Date of FDA Advisory Committee Review of Lomitapide NDA - Benzinga 08.14.12 | 09:08 am
- 16 Healthcare Stocks Deeply Discounted From Target Price - Seeking Alpha 01.12.12 | 09:01 am
- UPDATE: Aegerion Pharmaceuticals Files Registration Statement for Proposed Offering of 4.25M Shares - Benzinga 06.16.11 | 04:06 pm
